SCHEMBL4233295

SCHEMBL4233295

O=c1c2ccc(F)cc2nc(-c2ccc(F)cc2)n1NCc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
CYP3A4 P08684 5/20 0.48
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 3/20 0.42
ALDH1A1 P00352 4/20 0.42
HTT P42858 2/20 0.42
TP53 P04637 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
EGFR P00533 2/20 0.40
ADORA2A P29274 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237523 0.89 CYP3A4 (0.51) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4237651 0.89 SMN1; SMN2 (0.67) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4237411 0.85 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2APOLBALDH1A1
SCHEMBL4193513 0.84 SMN1; SMN2 (0.50) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4242390 0.82 ALDH1A1 (0.62) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4242353 0.82 SMN1; SMN2 (0.50) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL14161140 0.82 SMN1; SMN2 (0.50) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4239901 0.81 SMN1; SMN2 (0.54) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4233225 0.81 SMN1; SMN2 (0.56) SMN1; SMN2CYP3A4MEN1KMT2APOLB
SCHEMBL4201045 0.81 RXFP1 (0.52) SMN1; SMN2CYP3A4MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 SMN1; SMN2 4767/4885CYP3A4 1462/4885MEN1 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.